Abstract
This study aimed to investigate the correlation between complement C1q tumor necrosis factor-related protein 1 (CTRP1) and subclinical target organ damage (STOD) in essential hypertension (EH). 720 patients were enrolled in this study, including 360 healthy subjects and 360 patients with EH. The EH group included 183 patients complicated with STOD and 177 patients without STOD. In the STOD group, there were 87 patients with left ventricular hypertrophy (LVH), 32 patients with microalbuminuria (MAU), and 58 patients with complication of LVH and MAU. Enzyme-linked immunosorbent assay (ELISA) was used to detect the CTRP1, adiponectin (APN), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). We found that CTRP1 levels were higher in patients with EH than those in healthy subjects; moreover, the level of CTRP1 of patients in the group complicated with EH and STOD was increased compared with EH patients without STOD. CTRP1 levels in the group complicated with LVH and MAU were significantly higher than those in the LVH group and the MAU group. Furthermore, APN, CTRP1, and IL-6 were three factors that influenced the STOD of EH patients, among which CTRP1 and IL6 were positively related with the complication of hypertension and STOD. In conclusion, CTRP1 levels are increased and associated with the STOD (heart and kidney) in essential hypertension, which can be regarded as a novel biomarker in the prediction of prognosis for patients with essential hypertension.
Highlights
Hypertension accounts for the largest amount of attributable cardiovascular (CV) mortality in the world
We demonstrated that C1q tumor necrosis factor-related protein 1 (CTRP1) levels were increased in essential hypertension (EH) patients compared with healthy subjects and the CTRP1 levels in the hypertensive patients with subclinical target organ damage (STOD) were significantly higher than those in the patients without
This study indicated that CTRP1 might be the risk of STOD in essential hypertension
Summary
Hypertension accounts for the largest amount of attributable cardiovascular (CV) mortality in the world. Evidence of STOD may help to make the choice of the appropriate therapeutic pharmacological strategy in hypertensive patients. To this purpose, biomarkers are increasingly being used to assess STOD at increasingly early stage. Hypertensive patients have increased CTRP1 levels, and CTRP1 stimulates aldosterone production via upregulation of the transcription of cytochrome P450 11βhydroxylase 2 (Cyp11b2), which is the rate-limiting enzyme for aldosterone production [10]. These studies support the view that CTRP1 plays an important role in the regulation of cardiovascular function. The relationship between CTRP1 and STOD in essential hypertension remains unknown
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
